New hope for lung cancer patients with brain tumors: drug duo enters trial

NCT ID NCT07197008

Not yet recruiting Disease control Sponsor: Li-kun Chen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs, Sacituzumab tirumotecan and bevacizumab, in 50 people with a specific type of lung cancer (EGFR-mutant nonsquamous NSCLC) that has spread to the brain and no longer responds to standard targeted therapy. The goal is to see if the combination can shrink brain tumors and slow disease progression. Participants receive the drugs by IV every two weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab
What this could lead to: If successful, this combination could offer a new treatment option for patients with EGFR-mutant lung cancer that has spread to the brain and stopped responding to standard therapy.
What could go wrong: This is a small, early-phase (Phase 2) single-arm study with no comparison group, so results may not be definitive. The combination may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR-MUTATED NONSQUAMOUS NON-SMALL CELL LUNG CANCER WITH BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.